Physician profile
Timothy Y Wei
NPI 1093762825
$24,167.29
in general payments reported to CMS, 2019-2025
21 companies · $909 in 2025
The $909 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $8,618 · 2021: $11K · 2022: $644 · 2023: $1,118 · 2024: $1,076 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,102.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $11,522.23 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Allergan, INC. | $10,705.85 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $327.89 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $283.84 | 2019-2023 | Aimovig |
| Neurocrine Biosciences, INC. | $268.92 | 2024-2025 | Ingrezza |
| Ucb, INC. | $169.20 | 2019-2025 | Briviact |
| Bausch Health US, LLC | $153.41 | 2019 | |
| Boston Scientific Corporation | $115.25 | 2023 | |
| Csl Behring | $111.12 | 2025 | Hizentra, Privigen |
| Janssen Pharmaceuticals, INC | $99.00 | 2021 | |
| Pfizer INC. | $65.31 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $63.14 | 2024 | Ultomiris |
| Lilly USA, LLC | $62.74 | 2022-2025 | Kisunla |
| Amneal Pharmaceuticals LLC | $57.03 | 2023-2025 | Rytary, Crexont |
| Eisai INC. | $49.46 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.24 | 2024 | Rexulti |
| Alnylam Pharmaceuticals INC. | $21.74 | 2023 | Amvuttra |
| Scilex Pharmaceuticals INC. | $20.64 | 2023 | Ztlido |
| Genentech USA, INC. | $17.76 | 2023 | Ocrevus, Enspryng |
| Tanabe Pharma America, INC. | $17.71 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.